To investigate genes involved in pulmonary carcinogenesis and those related to sensitivity of nonsmall cell lung cancers (NSCLCs) to therapeutic drugs, we performed cDNA microarray analysis of 37 NSCLCs after lasercapture microdissection of cancer cells from primary tumors. A clustering algorithm applied to the expression data easily distinguished two major histological types of non-small cell lung cancer, adenocarcinoma and squamous cell carcinoma. Subsequent analysis of the 18 adenocarcinomas identified 40 genes whose expression levels could separate cases with lymph-node metastasis from those without metastasis. In addition, we compared the expression data with measurements of the sensitivity of surgically dissected NSCLC specimens to six anti-cancer drugs (docetaxel, paclitaxel, irinotecan, cisplatin, gemcitabine, and vinorelbine), as measured by the CD-DST (collagen gel droplet embedded culture-drug sensitivity test) method. We found significant associations between expression levels of dozens of genes and chemosensitivity of NSCLCs. Our results provide valuable information for eventually identifying predictive markers and novel therapeutic target molecules for this type of cancer.
Introduction
Lung cancer is one of the most commonly fatal of human tumors. Many genetic alterations associated with development and progression of lung cancer have been reported, but the precise molecular mechanisms remain unclear (Sozzi, 2001) . Although some of these genetic changes can aid prognostic efforts and predictions of metastatic risk or response to certain treatments, information about a single or a limited number of molecular markers generally fails to provide satisfactory results for clinical diagnosis of non-small cell lung cancers (NSCLCs) (Mitsudomi et al., 2000; Watine, 2000; Niklinski et al., 2001) . However, new technologies such as analysis of gene-expression profiles on cDNA microarrays enable us to perform comprehensive analyses of gene expression in cancer cells, and can reveal detailed phenotypic and biological information about them (Golub et al., 1999; Pomeroy et al., 2002; van 't Veer et al., 2002) . Systematic analysis of expression levels among thousands of genes is also a useful approach to identification of unknown molecules involved in the pathways of carcinogenesis; those discoveries can indicate targets for development of novel anti-cancer drugs.
Using a cDNA microarray containing 23 040 genes, we obtained comprehensive gene-expression profiles of 37 non-small cell lung cancers. We report here the discovery that certain genes are expressed differently between the two most common histological types of NSCLC, adenocarcinomas and squamous cell carcinomas (SCCs). In the process we identified molecular markers with the potential of predicting lymph-node metastasis and/or sensitivity to anti-cancer drugs, and discovered some important molecular characteristics of NSCLC that could eventually guide personalized therapies.
Results

Cluster analysis of gene expression
We first applied a two-dimensional hierarchical clustering algorithm to analyse similarities among samples and among genes, using data obtained from expression profiles of all 37 NSCLC samples ( Figure 1a ).
We excluded genes from further analysis when Cy3-or Cy5-fluorescence intensities were below the cutoff value, as described previously and selected a set of genes for which valid values could be obtained in more than 95% of the cases examined. We also excluded genes with observed standard deviations of o1.0. The 899 genes that passed through this cutoff filter were analysed further.
In the sample axis (horizontal) in Figure 1a , 39 samples (two cases were examined in duplicate to validate the reproducibility and reliability of our experimental procedure) from 37 cases were clustered into two major groups on the basis of their expression profiles. The dendrogram shown at the top of Figure 1a , represents similarities in expression patterns among individual cases; the shorter the branches are, the greater the similarities. The two duplicated cases (Nos. 6 and 12) that were labelled and hybridized in independent experiments were clustered most closely within the same group. The identical genes spotted on Figure 1 (A) Dendrogram of two-dimensional hierarchical clustering analysis of 899 genes across 39 samples from 37 cases of nonsmall cell lung cancer. The color of each well represents with red and green indicating transcript levels, respectively, above and below the median for that gene across all samples. Black, unchanged expression; gray, no detectable expression. In the horizontal axis representing 37 NSCLCs, adenocarcinomas and SCCs were separated into two trunks. In the vertical axis, the 899 genes were clustered in different branches according to similarities in relative expression ratio. On the right side of the cluster, color standards were shown. (B) Gene clusters with increased relative expression in adenocarcinomas (a), and in SCCs (b). Genes that appear more than once represent identical genes spotted on different sets of slides. (C) 'Non-authorized' cluster analysis of 22 adenocarcinomas appeared in a. In the sample axis, the 22 adenocarcinomas were separated into two trunks according to their lymph-node status Expression profiles of non-small cell lung cancer T Kikuchi et al 2193 different positions on the slide glasses were also clustered into the adjacent rows. These results supported the reproducibility and reliability of our experimental procedures. Of the 37 cases, the 22 adenocarcinomas clustered into one major group and the 14 SCCs clustered into the other. The single adenosquamous cell carcinoma (No. 25) fell into the SCC cluster. Clearly, adenocarcinoma and SCC appeared to have specific and different gene-expression profiles that could disclose the molecular nature of etiological differences.
Therefore, we focused on transcripts that were differentially expressed between SCCs and adenocarcinomas (Figure 1b) . Genes belonging to cluster (a) including SFTPB, FOLR1, and MMP-7 were more abundantly expressed in adenocarcinomas than in SCCs, while genes in cluster (b) were more abundantly expressed in SCCs than in adenocarcinomas. SFTPB is essential for the maintenance of respiratory function in type II alveolar cells (Vamvakopoulos et al., 1995) . FOLR1 and MMP-7 (matrilysin) were highly expressed in adenocarcinomas, and the overexpression of MMP-7 was indicated to have tendencies toward lymph-node or distant metastases (Franklin et al., 1994; Kawano et al., 1997) . Cluster (b) included KIAA0728, a gene expressed preferentially in SCCs (McDoniels-Silvers et al., 2002) and PFN2, an actin-related protein. This cluster also contained cytoskeletal genes (keratins 6, 8, 13, and 19 , and collagen types 4 and 6) that were already known to be more abundantly expressed in SCCs than in adenocarcinomas.
As the gene-expression profiles we obtained in the present study clearly separated lung adenocarcinomas from SCCs, we considered that expression profiles should help to elucidate differences in clinical course. Hence, we decided to perform the following analyses: (1) further hierarchical clustering of the 22 adenocarcinoma samples, (2) an attempt to identify genes correlated with absence or presence of lymph-node metastasis; and (3) screening of candidate genes for association with chemosensitivity.
Cluster analysis of adenocarcinomas
The two-dimensional hierarchical cluster analysis shown in Figure 1c represents the relationship between expression levels of certain genes and clinical features of the 22 adenocarcinomas. In all, ten of those 22 patients had lymph-node metastasis at the time of surgery; 11 had none; and one (case No. 1) had no lymphnode involvement but had suffered a distant metastasis. We selected 107 genes for which valid expression data were obtained in at least 90% cases and that revealed standard deviations of more than 1.5. All except four of the 22 adenocarcinomas fell into two major groups according to their status of lymph-node metastasis at the time of surgery; two cases (Nos. 28 and 35) without lymph-node metastasis were included in the branch corresponding to lymph-node positives, and one case (No. 45) with lymph-node metastasis was miss-assigned to the node-negative group. Case No. 1, with no lymphnode metastasis but with distant metastasis, was included in the node-positive branch. One case (No. 38) having a large tumor with a T factor (Primary tumor in UICC TNM classification) of 4 but no node metastasis, fell properly within the node-negative cluster. The clustering results shown in Figure 1c implied a possibility of molecular diagnosis for metastatic risk, on the basis of molecular classification using expression profiles.
To attempt establishment of a predictive scoring system for lymph-node metastasis using expression profiles of selected genes, we compared the expression profiles of nine node-positive cases and nine nodenegative cases whose T factors were 1 or 2. We first selected genes using two criteria: (1) signal intensities higher than the cutoff level in at least 80% of the cases; (2) |Med r ÀMed n |^0.5, where Med indicates the median derived from log-transformed relative expression ratios in node-positive cases or -negative cases. Then we carried out a permutation test to select genes that might be applicable for separating these two groups (see Materials and methods). As a result, 93 genes were listed as candidates, as they showed permutation Pvalues of less than 0.01. We rank-ordered these candidates on the basis of the significance of their permutation P-values and calculated the prediction score by the leave-one-out test for cross-validation, using the top 5, 10, 15, 20, 25, 30, etc. in increments of 5, of the 93 genes on the rank-ordered list. We calculated a classification score (CS) for each set of genes to estimate the number of discriminating genes that could provide the best separation of the two groups. As shown in Figure 2a , we obtained the best separation of nodepositive from node-negative cases when we used only the top 40-ranked genes in our candidate list for calculating the scores. Hierarchical clustering analysis using this set of genes, which included three ESTs, clearly subclassified all 18 adenocarcinoma cases into one of two groups according to lymph-node status. This group of 40 genes included some key factors whose possible roles in metastasis had been indicated previously: NESH (Ichigotani et al., 2002) , ARHA (Fukata and Kaibuchi, 2001) , DBI (Wieland et al., 1999) , and TACSTD1 (Meyaard et al., 2001) . Finally, we introduced a numerical scoring algorithm that might be clinically applicable for predicting lymph-node metastasis, using the 40 selected genes. This ''Classification Score'' system clearly distinguished node-positive cases from nodenegative cases. To validate the scoring system, we calculated scores for two lymph-node-negative cases and two node-positive cases that had not been among those used for construction of the scoring system; three of the four cases were placed correctly according to their lymph-node status, but one case was placed to the borderline region (Figure 2b ).
Genes associated with sensitivity to anti-cancer drugs
To discover genes that might be associated with chemosensitivity, we then compared expression levels with chemosensitivity measured by the CD-DST, a method that estimates chemosensitivity in vitro without the influence of individual in vivo conditions such as variations in drug metabolism or performance status. Results of CD-DST experiments for six anti-cancer drugs are summarized in Figure 3a . Pearson's correlation coefficients between gene-expression levels and chemosensitivity of 22 adenocarcinomas or 11 SCCs to each of the six drugs were calculated (representative diagrams shown in Figure 3b , c). The dozens of genes we found to be associated with chemosensitivity (Po0.01) are listed in Table 1 and a representative list appears in Table 2 . A statistical analysis of the 22 adenocarcinomas indicated that two of these genes were commonly associated with sensitivity to five of the six drugs examined, three genes with four drugs, and six genes with three drugs. Similarly, among the 11 SCCs one gene was associated with chemosensitivity to four drugs, and three genes with three drugs. Expression levels of seven genes, five of them ESTs, showed significant correlation with chemosensitivity of both adenocarcinomas and SCCs to any of the six drugs analysed.
Discussion
The cDNA microarray method is now widely used to analyse expression of thousands of genes simultaneously in cancer tissues, but contamination of tumors by normal epithelial, stromal immune cells presents problems for obtaining accurate expression profiles. To avoid this, in our previous works we coupled the laser-capture microdissection (LCM) technique (Emmert-Buck et al., 1996) with microarray analysis of tumors originating in colon, liver, and stomach Okabe et al., 2001; Lin et al., 2002) . In view of significant differences in the proportions of cancer cells in various tumor samples, in the work reported here we also applied LCM before analysing expression profiles of 37 NSCLCs that included 22 adenocarcinomas, 14 SCCs, and one adenosquamouscell carcinoma.
Although 'NSCLC' can refer to different histological subtypes, in clinical settings all are classified together and patients are often provided the same chemotherapy, particularly in inoperable cases. The distinct geneexpression profiles we observed between adenocarcinomas and SCCs of the lung (Figure 1a ) clearly suggested that these two histologically distinct lung cancers have different biological natures. Through a computational analysis we selected genes that were able to separate adenocarcinoma from SCC as well as genes that are likely to be associated with chemosensitivity. CDC20, which is known to have an important role in G1/S transition (Luo et al., 2002) , was more highly expressed in SCCs than in adenocarcinomas. According to a recent report (Makino et al., 2001 ) treatment with PAC, a drug that binds to tubulin and induces CDC20 expression, results in apoptosis of tumor cells. Activation of CDC20 might therefore affect the sensitivity of SCCs to PAC. GPI, a gene formerly shown to be associated with sensitivity to CPM and MTX (Zembutsu et al., 2002) , was expressed preferentially in SCCs in our experiments; its related protein, GML, was indicated to be a useful marker for chemotherapy of esophageal cancers (Furuhata et al., 1996) .
Lymph-node metastasis is a key step in tumor progression and a risk factor for recurrence after surgery. Our data from an 'un-authorized' cluster analysis ( Figure 1c ) clearly separated cases with lymph-node metastasis from those without metastasis. This result suggested that diagnosis based on expression profiles may have great potential for providing information about the biological nature of cancer cells that cannot be obtained by conventional histological diagnosis under the light microscope. This subset of genes that contributed to separation of our two patient groups according to the status of lymph-node metastasis might serve as molecular markers for metastasis ( Figure 2a ). Previous studies (Bhattacharjee et al., 2001; Garber et al., 2001; Beer et al., 2002) also classified lung adenocarcinomas into some groups according to survival status by means of gene-expression profiles. However, they did not use the microdissection but used RNAs isolated from tumor masses. In this study we coupled the laser-capture microdissection (LCM) technique with microarray analysis that enabled us to obtain accurate molecular profiles of NSCLC without contamination of tumors by normal epithelial cells, infiltrating lymphocytes or stromal cells. Hence, we are confident that our approach should be more useful for identification of novel biological markers as well as for selection of treatment modalities for individual patients according to lymph-node status.
One of our goals is to establish a method for predicting chemosensitivity of lung cancers by molecular analysis. Previously, we reported a set of genes Expression profiles of non-small cell lung cancer T Kikuchi et al 2196 Figure 2 (a) Result of a two-dimensional hierarchical clustering analysis using 40 genes selected by a random-permutation test for establishing a predictive scoring system. In the horizontal axis, 18 samples (selected from adenocarcinoma cases (see a) whose T factors were 1 or 2) were classified into two trunks. In the vertical axis, 40 genes were clustered in different branches according to similarity in relative expression ratios. Genes in the lower main branch were preferentially expressed in cases involving lymph-node metastasis; those in the upper branch were more highly expressed in lymph-node-negative cases. (b) Strength of genes appearing in (a) for separating nonmetastatic (lymph-node-negative) tumors from metastatic (lymph-node-positive) tumors. Blue circles represent node-positive cases; red denotes negative cases. The yellow triangles represent a lymph-node-negative test cases that had not been used for establishing prediction scores. The brown triangles are lymphnode-positive test cases
Expression profiles of non-small cell lung cancer T Kikuchi et al 2197 associated with chemosensitivity using 85 xenografts (Zembutsu et al., 2002) . Other reports have also described chemosensitivity of tumors (Ueda et al., 1987; Furukawa et al., 1995; Salonga et al., 2000; Turton et al., 2001) , usually on the basis of survival periods or disease-free times as end points of a study. In contrast, we measured chemosensitivity by CD-DST using surgically resected tissues. The CD-DST technique has some clear advantages, in that we can measure chemosensitivity directly by the shrinking of tumor size in vitro without having to consider individual differences such as age, gender, past therapy received, or performance status, and this method of estimating chemosensitivity can yield results in a relatively short time.
Ours is the first report of genome-wide screening for genes associated with sensitivity of NSCLC to six anti-cancer drugs, using surgically resected material and combining cDNA microarray analysis with in vitro chemosensitivity assays. In this study, we identified dozens of candidate genes that were significantly associated with sensitivity to one or more of the six drugs we examined. In our previous work using 85 xenografts (Zembutsu et al., 2002) , YWHAQ was one of the candidate genes associated with sensitivity to CPM, ADR, and MMC. In the present analysis YWHAQ also revealed correlation between expression level and sensitivity to CPT-11, PAC, DOC, and GEM in adenocarcinomas. Additionally, members of the MRP family of transporters (Cole et al., 1992) are thought to play important roles in immortalization of cancer cells and in metabolism of anti-cancer drugs. A putative integral-membrane transporter, LC27, which appears to be up-regulated in HCCs (Kondoh et al., 2001) , showed significant correlation with sensitivity to PAC, DOC, and GEM in our experiments. These results underscore the reliability of our data in providing potential prognostic markers for cancer therapeutics. Although further validation using larger sets of clinical cases will be necessary, the data presented here represent initial clues as to Expression profiles of non-small cell lung cancer T Kikuchi et al 2198 particular genes involved in chemosensitivity of NSCLCs. Moreover, our gene-expression analysis revealed several novel findings about lung cancer from the viewpoint of molecular diagnosis, namely the differences in gene expression between adenocarcinomas and SCCs. It also revealed genes that are candidates for association with lymph-node metastasis. Comparing with previous studies, our results using the tumor cells purified by laser-capture microdissection provide more precise information that should be helpful for isolation of novel biological markers. Lastly, the profiles reported here may also yield valuable insights into the molecular events underlying pulmonary carcinogenesis and provide information for future targeted therapies and prevention of lung cancer.
Materials and methods
Patients and tissue samples
Primary lung cancers were obtained with informed consent from 37 patients (15 female and 22 male; median age 66.0 in a range of 46-79 years) who underwent lobectomy at the Keio University Hospital in Tokyo, Japan. Clinical information was obtained from medical records and each tumor was diagnosed according to histopathological subtype and grade by the pathologist; 22 of the 37 tumors were classified as adenocarcinomas, 14 as SCCs, and one as adenosquamous carcinoma. Clinical stage was judged according to the UICC TNM classification. No significant differences were observed between node-positive and node-negative cases with respect to age or sex. All samples were immediately frozen and embedded in TissueTek OCT medium (Sakura, Tokyo, Japan) and stored at À801C.
Laser-capture microdissection extraction of RNA and T7-based RNA amplification Cancer cells were selectively collected from the preserved samples using laser-capture microdissection . To minimize the effects during storage process and tissue collection, we carefully handled the cancer tissues by the same procedure. To check the quality of RNAs, total RNA extracted from the residual tissue of each case were electrophoresed under the degenerative agarose gel, and confirmed their quality by a presence of ribosomal RNA bands. Extraction of total RNA and T7-based amplification were performed as described previously (Okabe et al., 2001) . As a control probe, normal human lung poly(A) RNA (CLONTECH) was amplified in the same way; 2.5mg aliquots of amplified RNAs (aRNAs) from each cancerous tissue and from the control were reversely transcribed in the presence of Cy5-dCTP and Cy3-dCTP, respectively.
Preparation of the cDNA microarray
To obtain cDNAs for spotting on the glass slides, we performed RT-PCR for each gene as described previously . The PCR products were spotted on type VII glass-slides (Amersham Biosciences) with a Microarray Spotter Generation III (Amersham Biosciences); 4608 genes were spotted in duplicate on a single slide. We prepared five different sets of slides (total 23 040 genes), on each of which the same 52 housekeeping genes and two negativecontrol genes were spotted as well.
Hybridization and acquisition of data
Hybridization, washing and detection of signals were carried out as described previously (Okabe et al., 2001) . The fluorescence intensities of Cy5 (tumor) and Cy3 (control) for each target spot were adjusted so that the mean Cy5/Cy3 ratio of the 52 housekeeping genes was equal to one. Since data derived from low signal intensities are less reliable, we determined a cutoff value for signal intensities on each slide and excluded genes from further analysis when both Cy3 and Cy5 dyes gave signal intensities lower than the cutoff.
Cluster analysis of 37 NSCLCs according to gene-expression profiles
We applied a hierarchical clustering method to both genes and tumors. To obtain reproducible clusters for classification of the 37 samples, we selected 899 genes for which valid data were obtained in 95% of the experiments, and whose expression ratios varied by standard deviations of more than 1.0. The analysis was performed using web-available software ('Cluster' and 'TreeView') written by M Eisen (http:// genome-www5.stanford.edu/MicroArray/SMD/restech.html). Before applying the clustering algorithm, we log-transformed the fluorescence ratio for each spot and then mediancentered the data for each sample to remove experimental biases.
Cluster analysis of 22 adenocarcinomas
We analysed gene-expression patterns of the 22 adenocarcinoma samples and selected 107 genes for which values were obtainable from more than 90% of cases, with s.d.s >1.5. Clustering analysis was performed according to the method cited above.
Identification of genes responsible for lymph-node metastasis
We applied a random permutation test to identify genes that were expressed differently between cases with or without lymph-node metastasis. Mean (m) and s.d.s (s) were calculated from the log-transformed relative expression ratios of each gene in node-positive (r) and node-negative (n) cases. A discrimination score (DS) for each gene was defined as follows:
We carried out permutation tests to estimate the ability of individual genes to distinguish between node-positives and node-negatives; samples were randomly permutated between the two classes 10 000 times. Since the DS data set of each gene showed a normal distribution, we calculated a P-value for the user-defined grouping (Golub et al., 1999) . For this analysis, we applied the expression data of 18 cases whose T factors were either 1 or 2, consisting of nine lymph-node-positive and nine negative cases.
Calculation of prediction score
We calculated prediction scores according to procedures described previously (Golub et al., 1999) . Each gene (g i ) votes for either lymph-node-negative or lymph-node-positive depending on whether the expression level (x i ) in the sample is 
We summed the votes to obtain total votes for the nodenegative (V r ) and node-positive (V n ), and calculated PS values as follows: PS ¼ (V r ÀV n )/(V r +V n ), reflecting the margin of victory in the direction of either node-negative or nodepositive. PS values range from -1 to 1; a higher absolute value of PS reflects a stronger prediction.
Evaluation of classification and leave-one-out test
We calculated the classification score (CS) using prediction scores of lymph-node-negatives (PS r ) and node-positives (PS n ) in each gene set, as follows:
A larger value of CS indicates better separation of the two groups by the predictive-scoring system. For the leave-one-out test, one sample is withheld, the permutation P-value and mean expression levels are calculated using remaining samples, and the class of the withheld sample is subsequently evaluated by calculating its prediction score. We repeated this procedure for each of the 18 samples.
Evaluation of sensitivity to anti-cancer drugs using CD-DST Each tumor specimen was minced finely and aseptically with a scalpel, suspended in Hanks' balanced saline solution (HBSS), and digested in a cell-dispersion enzyme solution (10% EZ, Nitta Gelatin Inc., Osaka, Japan) at 371C for 1-3 h. The dispersed cancer cells were precipitated by centrifugation at 900 g for 3 min, filtered through an 80 mm nylon mesh, washed in HBSS, suspended in PCM-1 medium (Nitta Gelatin), and incubated in a CG-flask (Nitta Gelatin) in a CO 2 incubator at 371C for 24 h. The collagen gel in the CG-flask was dissolved in the cell-dispersion enzyme solution (10% EZ). This protocol allowed collection of viable cells only, because they were able to adhere to the collagen gel.
Collagen gel droplet-embedded culture The prepared tumorcell suspension was added to a collagen solution (Collagen Gel Culture Kit, Nitta Gelatin) to produce a final cell density of 1 Â 10 5 cells/ml. Three drops of collagen-cell mixture (30 ml/ drop) were placed in each well of a six-well plate and allowed to gel at 371C in a CO 2 incubator. The final concentration was about 3 Â 10 3 cells per collagen gel droplet. DF medium (3 ml, Nissui Pharmaceutical Inc., Tokyo, Japan) containing 10% fetal bovine serum (FBS, Gibco, Gaithersberg, MD, USA) was overlaid on each well 1h later, and samples were incubated overnight at 371C in a CO 2 atmosphere.
In vitro chemosensitivity test We introduced into the wells each of six anti-cancer drugs (final concentration for each drug was adjusted to each area under the curve (AUC). After incubation for 24 h the drug-containing media were removed and each well was rinsed with 3 ml of HBSS twice, overlaid with 4 ml of PCM-2 medium (Serum Free Medium, Nitta Gelatin), and incubated for 7 days. Neutral red was then added to each well at a final concentration of 50 mg/ml, and the cultures were incubated with the dye for 2 h. Each collagen droplet was fixed with 10% neutral formalin buffer, washed in Expression profiles of non-small cell lung cancer T Kikuchi et al water, air dried, and quantified by image analysis.
In vitro chemosensitivity was measured as the T/C ratio, where T represented the total cell volume of the treated group and C represented the total cell volume of the untreated group.
Identification of genes associated with anti-cancer drugs
To estimate correlation between the expression ratio (log 2 Cy5/ Cy3) of a given gene and sensitivity to each anti-cancer drug estimated by the CD-DST, we calculated a Pearson's correlation coefficient by the following formula:
where x i represented the log expression ratio (log 2 Cy5/Cy3) of gene x in sample i, while y i represented sensitivity (1-T/C) of sample i to drug y. x mean represented the mean of the log expression ratio of gene x, and y mean represented the mean sensitivity (1ÀT/C) of the drug. We selected genes that showed significant correlation (Po0.01) and an absolute value of the slope of the regression line greater than 1.5, when the difference of the T/C values between the most and the least sensitive samples was fixed as one.
Abbreviations NSCLC, non-small cell lung cancer; SCC, squamous cell arcinoma; CD-DST, collagen gel droplet embedded culturedrug sensitivity test; NESH, NESH PROTEIN; ARHA, ras homolog gene member A; DBI, diazepam binding inhibitor; TACSTD1, tumor-associated calcium signal transducer 1; DOC, docetaxel; PAC, paclitaxel; CPT-11, irinotecan; CDDP, cisplatin; GEM, gemcitabine; NVB, vinorelbine; CPM, cyclophosphamide; ADR, adriamycin; MMC, mitomycin; T/C (%), relative tumor volume with respect to controls; GPI, glucose-6-phosphate isomerase; GML, glycosylphosphatidylinositol-anchored molecule-like protein; YWHAQ, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein
